Compare Otis Worldwide Corp (OTIS) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Otis Worldwide Corp vs Travere Therapeutics Inc. Common Stock — how do they compare? Otis Worldwide Corp trades at $69.11 (market cap $25.76B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Otis Worldwide Corp is far larger — about 5.3× Travere Therapeutics Inc. Common Stock's market cap, and Otis Worldwide Corp pays a 2.6% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Otis Worldwide Corp for 66 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| OTIS | TVTX | |
|---|---|---|
Market Cap | $25.76B | $4.88B |
Volume | 6,407,907 | 1,668,577 |
Sector | Industrials | Health |
52-Week High | $93.62 | $67.52 |
52-Week Low | $64.05 | $26.79 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $33.80B | $5.01B |
Dividend Yield | 2.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Otis Worldwide trades at $69.11, up 3.54% today but near its 52-week low amid bearish technical signals and recent earnings misses. The company maintains stable revenue around $14.4B with a 10.17% net margin, though service margins face pressure from labor costs. Analyst consensus is mixed with a $87 price target, while institutional investors show varied positioning through recent acquisitions and sales.
The stock presents a defensive opportunity given its dominant elevator service franchise, but near-term upside is limited by margin pressures and China demand uncertainty. Key risks include execution on service margin expansion and macroeconomic headwinds affecting new equipment orders.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
